Table 2.

Improved or sustained GL-3 clearance from renal cells of patients who had Fabry disease and underwent long-term agalsidase β therapy^a

Renal Cell Type	No. Evaluated at Month 6	No. (%) with Score of 0	No. Evaluated at Month 54^b	No. (%) with Score of 0
Capillary endothelial cells	49	47 (96)	8	8 (100)
Glomerular endothelial cells	35	35 (100)	5	5 (100)
Mesangial cells	35	34 (97)	5	5 (100)
Interstitial cells	48	43 (90)	7	5 (71)
Noncapillary endothelial cells	44	40 (91)	6	6 (100)
Noncapillary smooth muscle cells	43	0 (0)	6	0 (0)

↵^a Patients with data at both pretreatment and month 6 or pretreatment and month 54 are summarized. GL-3, globotriaosylceramide.
↵^b Of the extension study.